Neurodegenerative diseases are characterized by the accumulation of misfolded proteins in the brain and a large loss of specific neurons. Diseases such as Parkinson’s Disease, Alzheimer’s Disease, and Amyotrophic Lateral Diseases have proven to be multifactorial conditions where a large variety of cellular and molecular processes are involved, inducing life-quality detrimental changes. Neurological disease can manifest as cognitive decline, memory impairment, behavioral disorders, aphasia, tremors, movement capacity reduction, neuropsychiatric symptoms, sleep disorders, among others.

Mesenchymal Stem Cells (MSCs) have been studied during the last decades as an alternative to treat tissue damage or degeneration caused by injury, aging o disease.

When administered, MSCs have shown to be able to target and migrate to injured/inflamed body areas. The MSCs’ communication with the immune cells also allows them to regulate their function, ameliorating pro-inflammatory responses. MSCs, either from autologous (self) or allogeneic (others) sources, have proven to be safe and effective. Therefore, among other therapeutic strategies, MSCs administration can be considered a great option to explore as a plan to improve neurological patients’ quality of life.

Yao P, Zhou L, Zhu L, Zhou B, Yu Q. Mesenchymal Stem Cells: a Potential Therapeutic Strategy for Neurodegenerative Diseases. Eur Neurol. 2020. 83:235-41.

Michelle Ibarra